Leadless Cardiac Pacemaker Patents: Top Companies & Trends 2026
A data-backed look at leadless cardiac pacemaker patents: who leads filings, how the technology composition breaks down across IPC classes, and where the filing trend is heading through 2026.
Filing growth = 2021 (23 records) → 2024 (26); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 665 records in scope (CR5), not the ranked leaders only.
What the leadless cardiac pacemaker patent record shows
Leadless cardiac pacemakers replace the traditional pacemaker’s lead wire and subcutaneous pocket with a self-contained capsule delivered directly into the heart chamber. The patent record in scope covers 665 records filed between 2015 and 2026, spanning fixation mechanisms, battery and electronics packaging, and the wireless communication schemes used for rate response and inter-device signalling. Publication lags filing by roughly 18 months, so the most recent filing years in this dataset are understated and should not be read as a slowdown.
Filing activity concentrates heavily around device-level claims on electrotherapy and pacing function, with a smaller but consistent presence of claims touching diagnosis and surgical delivery, fluid-handling devices, and the wireless transmission hardware that lets a leadless pacemaker communicate without a lead.
Filing trend and technology composition
The two views below cover the same 665 records: one tracks when the applications were filed, the other tracks what they claim, by IPC subclass.
A rising filing curve since 2021
Filings peaked at 96 in 2017, then eased before climbing again: the count moved from 23 in 2021 to 26 in 2024, a 13% increase over that three-year span. Treat 2025 and 2026 figures as incomplete rather than as evidence of decline, since publication lag has not yet caught up with those filing years.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Electrotherapy claims dominate, with fixation and wireless hardware in the minority
A61N (electrotherapy & radiation therapy) appears on 89.9% of the 665 records, confirming that pacing and stimulation function is the primary claim target across the field. A61B (diagnosis & surgery) reaches 28.4%, reflecting delivery-catheter and implantation-procedure claims, while A61M (devices for body fluids) sits at 8.7%. Wireless communication hardware — H04B, H01Q — and battery or packaging classes such as H01M and H05K each cover single-digit shares, marking them as adjacent rather than core claim territory.
Shares are the percentage of the 665 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cardiovascular Devices: Leadless Cardiac Pacemaker Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cardiovascular devices: leadless cardiac pacemaker patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited leadless cardiac pacemaker patents
US9511236B2 — Leadless cardiac pacemaker with integral battery and redundant welds
A leadless cardiac pacemaker that does not require a separate hermetic housing surrounding the battery and electronics compartments is provided. The cardiac pacemaker can include a battery disposed in a battery housing and a set of electronics disposed in an electronics housing. In some embodiments, the battery housing and the electronics housing can comprise an external surface of the pacemaker. The pacemaker can include a first set of welds separating the battery from the set of electronics, and a second set of welds separating the set of electronics and the battery from an exterior of the housing. Various embodiments for achieving dual-redundant welds are also provided.Filed by Pacesetter, Inc., granted 2016-12-06. The claims center on eliminating a separate hermetic housing by using dual-redundant welds to isolate battery from electronics within a single external shell.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20090082828A1 | Leadless Cardiac Pacemaker with Secondary Fixation Capability | 459 |
| 2 | US20070088394A1 | Leadless cardiac pacemaker system for usage in combination with an implantable cardioverter-defibrillator | 361 |
| 3 | US20070088397A1 | Leadless cardiac pacemaker system with conductive communication | 359 |
| 4 | US20120109236A1 | Leadless cardiac pacemaker with conducted communication | 344 |
| 5 | US7937148B2 | Rate responsive leadless cardiac pacemaker | 312 |
| 6 | US20120116489A1 | Leadless Cardiac Pacemaker with Anti-Unscrewing Feature | 305 |
| 7 | US20120165827A1 | Pacemaker Retrieval Systems and Methods | 300 |
| 8 | US20120095539A1 | Delivery Catheter Systems and Methods | 290 |
| 9 | US20110077708A1 | MRI Compatible Leadless Cardiac Pacemaker | 286 |
| 10 | US8457742B2 | Leadless cardiac pacemaker system for usage in combination with an implantable cardioverter-defibrillator | 279 |
Ranked by citation count within the searched corpus; older filings accumulate more citations by virtue of age, so treat this as a signal of influence rather than of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four figures from this dataset carry direct implications for where to file, whom to watch, and what claim territory is already crowded.
Filing sits with a small group of incumbents
Five assignees hold 606 of the 665 records in scope, a 91.1% share. That leaves a thin long tail of remaining entities, several with only one or two filings apiece. A new entrant should assume core capsule and fixation claims are already dense, and look toward the adjacent classes with lighter coverage instead.
Activity is climbing, not cooling
Filings rose from 23 in 2021 to 26 in 2024, the last year with a complete count once publication lag is accounted for. That contradicts any read of the 2017 peak as a one-off high point followed by retreat; the field has kept adding filings through its most recent complete year.
Electrotherapy claims are the field's core
Almost nine in ten records touch A61N, the electrotherapy and radiation-therapy subclass covering pacing and stimulation function itself. Diagnosis and surgical delivery claims (A61B) reach 28.4%, well below that, and fluid-device claims (A61M) sit at 8.7%, marking a clear hierarchy of where claim density actually lives.
Wireless and battery hardware stay a minority claim
Transmission hardware (H04B) appears on just 4.2% of records, and antenna claims (H01Q) on 1.8%; battery chemistry (H01M) covers 0.9%. These are the branches supporting inter-device communication and power, and their low density relative to the core electrotherapy claims points to comparatively open claim space.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cardiovascular devices: leadless cardiac pacemaker patent landscape, with the prior art for and against each one.
Where to take this analysis
The figures above describe the shape of the field. Turning that shape into a filing or freedom-to-operate decision means drilling into specific claims and specific assignees.
Map claim language against the top five holdings
With 91.1% of records held by five assignees, a claim chart against their granted independent claims is the fastest way to see what is actually blocked versus what merely looks crowded from IPC counts alone.
Run a claim comparison in EurekaTrack the under-claimed wireless and battery branches
H04B, H01Q and H01M each sit under 5% of records. That is a narrower, more tractable set of prior art to review before drafting a first claim in inter-device communication or power management.
Explore white space in EurekaWatch the co-assignee clusters for licensing signals
Recurring inventor pairs across filings can indicate active internal teams or licensing relationships worth monitoring ahead of a competitive filing.
Search assignee networks in EurekaLeadless cardiac pacemaker patents: common questions
Filing in this field is highly concentrated: five assignees hold 606 of the 665 records in scope, a 91.1% combined share, and the single largest holder accounts for 258 records on its own. The next tier of holders drops off sharply, with the fifth-ranked assignee at only 10 records and the tenth at 4. Anyone assessing competitive position should treat the leading assignee's granted claims as the primary reference point, since the remaining field is a long tail of much smaller filers.
Yes, based on the most recent complete filing years. Filings rose from 23 in 2021 to 26 in 2024, a 13% increase, after an earlier peak of 96 filings in 2017. Because publication typically lags filing by about 18 months, the lower counts shown for 2025 and 2026 reflect incomplete data rather than a real drop in activity, so they should not be read as the field cooling off.
The dominant claim territory is electrotherapy and pacing function itself, captured under IPC class A61N, which appears on 89.9% of the 665 records in scope. Diagnosis and surgical delivery claims (A61B) follow at 28.4%, covering implantation catheters and procedural methods, while devices for body fluids (A61M) reach 8.7%. Smaller shares cover wireless transmission hardware, antennas, batteries and printed circuit assemblies, all under 5% each, marking these as supporting rather than core claim areas.
US9511236B2, assigned to Pacesetter, Inc. and granted in December 2016, covers a leadless pacemaker design that avoids a separate hermetic housing around the battery and electronics by using a dual set of redundant welds instead. That specific packaging approach — welds separating battery from electronics, and a second set separating both from the exterior — is what the claims tie down, not leadless pacing generally. A design that uses a conventional hermetic housing, or a different weld or seal architecture, would sit outside this particular claim scope.
The clearest under-claimed branches are the ones furthest from the core electrotherapy claims: wireless transmission hardware (H04B) at 4.2% of records, antenna design (H01Q) at 1.8%, battery chemistry (H01M) at 0.9%, and mechanical fixation components under F16C at 0.8%. These low shares, against a field where core pacing claims sit at 89.9%, suggest more room to file novel claims around inter-device communication, power source design, and fixation hardware than around pacing function itself.
Research Cardiovascular Devices: Leadless Cardiac Pacemaker Patent Landscape in depth with Eureka
Go past this page: query the whole cardiovascular devices: leadless cardiac pacemaker patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.